timothy sykes logo
ImmunityBio Explores Innovations in Cancer Treatment Thumbnail
G Google News

ImmunityBio Explores Innovations in Cancer Treatment

BRYCE TUOHEY•UPDATED NOV. 28, 2025, 11:32 AM ET
Reviewed by Matt Monacoand Fact-checked by Bryce Tuohey

ImmunityBio Inc.’s stocks have been trading up by 11.03 percent amid positive clinical trial results and investor optimism.

Key Takeaways

  • With immunotherapy gaining favor over chemotherapy due to less severe side effects, patients with non-muscle invasive bladder cancer are calling for more insightful consultations about their treatment options.
  • ImmunityBio has showcased impressive sales figures for 2025, reporting a significant 467% growth, largely driven by its demand for the product ANKTIVA.
  • Encouraging results from ImmunityBio’s clinical trials in treating various cancers have catalyzed an initiation of advanced-stage trials for glioblastoma and non-small cell lung cancer.
  • A Q3 earnings report reveals that ImmunityBio exceeded profit expectations and saw a notable increase in unit sales for its hallmark drug targeting non-muscle invasive bladder cancer.

Candlestick Chart

Live Update At 11:32:30 EST: On Friday, November 28, 2025 ImmunityBio Inc. stock [NASDAQ: IBRX] is trending up by 11.03%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

ImmunityBio Inc. has emerged as a formidable player in the biotech sphere. The recent financial performance of the company highlights a robust pathway paved with growth opportunities and strategic advancements. For the fiscal year 2025, IBRX saw a staggering 467% rise in sales, generating revenue of $75M in the process. This was majorly attributed to the brand’s groundbreaking drug, ANKTIVA, which has proven to be a beacon of hope for patients grappling with non-muscle invasive bladder cancer.

The third-quarter earnings report presented an unexpected uptick, outperforming analysts’ predictions, with earnings per share beating the consensus by 4 cents. ANKTIVA’s addition as a leading treatment choice for a major drug contracting organization is indeed significant, supplementing the strong clinical developments underway.

More Breaking News

Turning to the balance sheet, the company’s cash position stands strong at $60M, supporting ongoing R&D and expansions. Though faced with some financial pressures, indicated by the negative profitability margins and substantial operating expenses, the firm is well-geared to capitalize on its current momentum. The leverage ratios, although incomplete, alongside substantial equity investment, suggest an inherent drive towards expansive medical breakthroughs and delivery of long-term shareholder value.

Investor Confidence on the Rise

The waves of optimism surrounding ImmunityBio’s growth trajectory cannot be understated. The surge in unit sales for ANKTIVA and promising advancements in clinical trials demonstrate the company’s commitment to pioneering new therapeutic frontiers in immunotherapy.

The positive reception from large-scale contracting organizations signals broader acceptance and trust in ImmunityBio’s therapeutic solutions, fueling on-track expansion in burgeoning markets. The strategic emphasis on diversifying and strengthening research pipelines suggests trust in delivering substantial clinical benefits and favorable financial outcomes in the long term, cementing investor confidence in its vision.

Market Reactions

ImmunityBio’s stock price continues to experience a dynamic shift, driven by strategic accomplishments and the fruitful performance of its flagship therapies. While showcasing considerable earnings upside and robust clinical trial pipelines, the market perceives ImmunityBio as a catalyst for potential disruption within oncology therapeutics—an arena ripe with innovation.

The preference for immunotherapy over conventional methods speaks volumes about the shifting paradigms in cancer care, positioning ImmunityBio at the forefront of a transformative shift. This shift in treatment approach and marked improvement in patient experience reinforce ImmunityBio’s competitive advantage in the field, driving positivity among stakeholders.

In recapping recent valuations, the stock’s recent movement—yet to show cumulative rallying strength—may soon see marked gains, contingent on clinical credibility and financial resilience amid rigorous operational landscapes.

Conclusion

ImmunityBio’s latest endeavors, coupled with its soaring financial metrics, fortify its position as a lead entity in advancing cancer treatment modalities. The confluence of strong financial performance, promising trial outcomes, and wider industry acceptance uplifts ImmunityBio’s market stance.

With a solid focus on sustainable growth, driven by innovation and strategic collaborations, ImmunityBio is poised to redefine treatment norms, promising enduring impact across the oncology spectrum. Yet, in the trading world, it’s vital to remember what millionaire penny stock trader and teacher Tim Sykes says, “There is always another play around the corner; don’t chase just because you feel FOMO.” As market sentiment remains buoyant, the unfolding narrative, marked by prolific strategic decisions and commitment to pioneering care solutions, awaits to etch the next chapter in the annals of groundbreaking cancer therapeutics.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Click Here for a Millionaire's POV on Trading IBRX

Millionaire's
POV on IBRX

Don't miss the next
big breakout.

GET POV
Tim Sykes

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”